Wilfried Mullens, Jeroen Dauw, Finn Gustafsson, Alexandre Mebazaa, Jan Steffel, Klaus K Witte, Victoria Delgado, Cecilia Linde, Kevin Vernooy, Stefan D Anker, Ovidiu Chioncel, Davor Milicic, Gerd Hasenfuß, Piotr Ponikowski, Ralph Stephan von Bardeleben, Friedrich Koehler, Frank Ruschitzka, Kevin Damman, Ehud Schwammenthal, Jeffrey M Testani, Faiez Zannad, Michael Böhm, Martin R Cowie, Kenneth Dickstein, Tiny Jaarsma, Gerasimos Filippatos, Maurizio Volterrani, Thomas Thum, Stamatis Adamopoulos, Alain Cohen-Solal, Brenda Moura, Amina Rakisheva, Arsen Ristic, Antoni Bayes-Genis, Sophie Van Linthout, Carlo Gabriele Tocchetti, Gianluigi Savarese, Hadi Skouri, Marianna Adamo, Offer Amir, Mehmet Birhan Yilmaz, Maggie Simpson, Mariya Tokmakova, Arantxa González, Massimo Piepoli, Petar Seferovic, Marco Metra, Andrew J S Coats, Giuseppe M C Rosano
Implantable devices form an integral part of the management of patients with heart failure (HF) and provide adjunctive therapies in addition to cornerstone drug treatment. Although the number of these devices is growing, only few are supported by robust evidence. Current devices aim to improve haemodynamics, improve reverse remodelling, or provide electrical therapy. A number of these devices have guideline recommendations and some have been shown to improve outcomes such as cardiac resynchronization therapy, implantable cardioverter-defibrillators and long-term mechanical support...
January 25, 2024: European Journal of Heart Failure